Aerie Pharmaceuticals shares should be bought ahead of data, says Stifel After traveling with Aerie's management, Stifel believes there is a good chance that the Phase 2b data for the company's Roclatan will be positive. The firm expects the data to be released in late June/early July, and it recommends buying shares of Aerie ahead of the data release. It keeps a $24 price target and Buy rating on the shares.
News For AERI From The Last 14 Days
Check below for free stories on AERI the last two weeks.